Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect

Roche is stepping up the defense of its critical HER2 franchise, committing $70 million in upfront and near-term payments to secure global rights to Zion Pharma’s early-phase treatment of brain metastases.